Buy Like Buffett
Watchlist

Flagship explainer

How Maravai LifeSciences Holdings, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$186M · 100%Cost of revenue$152M · 82%Gross profit$34M · 18%Operating income−$215M · −116%Income before tax−$235M · −127%Income tax−$4.2M · −2%Net income−$131M · −70%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$186M100%
  • 10-K · FY 2025Filing detailsAccession 0001823239-26-000011 · filed Feb 26, 2026
Cost of revenue$152M82%
  • 10-K · FY 2025Filing detailsAccession 0001823239-26-000011 · filed Feb 26, 2026
$34M18%
  • 10-K · FY 2025Filing detailsAccession 0001823239-26-000011 · filed Feb 26, 2026
−$215M−116%
  • 10-K · FY 2025Filing detailsAccession 0001823239-26-000011 · filed Feb 26, 2026
Income before tax−$235M−127%
  • 10-K · FY 2025Filing detailsAccession 0001823239-26-000011 · filed Feb 26, 2026
Income tax−$4.2M−2%
  • 10-K · FY 2025Filing detailsAccession 0001823239-26-000011 · filed Feb 26, 2026
−$131M−70%
  • 10-K · FY 2025Filing detailsAccession 0001823239-26-000011 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001823239-26-000011 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full Maravai LifeSciences Holdings, Inc. analysis at Buy Like Buffett